Structure-activity relationship study on the P4 structure of macrocyclic BACE1 inhibitors

-Secretase (BACE1) is an aspartic protease involved in the production of amyloid peptide (A).A accumulation in the brain is hypothesized to underlie the pathogenesis of Alzheimer's disease (AD), hence it is reasoned that inhibiting BACE1 will play a crucial role in the treatment of AD.Previously, we have synthesized and evaluated peptidic BACE1 inhibitors containing a hydroxyethylamine (HEA) type isostere 1,2 and discovered a macrocyclic inhibitor, inhibitor 3, containing a hydrophobic bridge between the P1 and P3 side chains 3 .Despite displaying good activity, the membrane permeability of inhibitor 3 is constrained by high hydrophilicity, limiting its development as a drug.Therefore, we try to design macrocyclic derivatives of this inhibitor with lower hydrophilicity, to increase membrane permeability.In this study, the amino and carboxy groups of glutamic acid at the P4 position of inhibitor 3 significantly influence its hydrophilicity, hence some derivatives of inhibitor 3 with a less hydrophilic substituent at the P4 position were designed and synthesized, and their activities were evaluated.

Authors

Publication Details

Published
2024-09-20
DOI
https://doi.org/10.17952/37eps.2024.p1251
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Structure-activity relationship study on the P4 structure of macrocyclic BACE1 inhibitors

Shinya Oishi, Momoka Kawakita, Takuya Otani, Kazuya Kobayashi et al.
Computational Drug Discovery Methods
article

Structure-activity relationship study on the P4 structure of macrocyclic BACE1 inhibitors

Shinya Oishi, Momoka Kawakita, Takuya Otani, Kazuya Kobayashi, Yasaunao Hattori
article en

Abstract

-Secretase (BACE1) is an aspartic protease involved in the production of amyloid peptide (A).A accumulation in the brain is hypothesized to underlie the pathogenesis of Alzheimer's disease (AD), hence it is reasoned that inhibiting BACE1 will play a crucial role in the treatment of AD.Previously, we have synthesized and evaluated peptidic BACE1 inhibitors containing a hydroxyethylamine (HEA) type isostere 1,2 and discovered a macrocyclic inhibitor, inhibitor 3, containing a hydrophobic bridge between the P1 and P3 side chains 3 .Despite displaying good activity, the membrane permeability of inhibitor 3 is constrained by high hydrophilicity, limiting its development as a drug.Therefore, we try to design macrocyclic derivatives of this inhibitor with lower hydrophilicity, to increase membrane permeability.In this study, the amino and carboxy groups of glutamic acid at the P4 position of inhibitor 3 significantly influence its hydrophilicity, hence some derivatives of inhibitor 3 with a less hydrophilic substituent at the P4 position were designed and synthesized, and their activities were evaluated.

Openalex Percentile: Top 80%
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Structure-activity relationship study on the P4 structure of macrocyclic BACE1 inhibitors — Shinya Oishi, Momoka Kawakita, et al. · (2024) | TGRS Research Map | TGRS